Investors

2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
May 02, 2016
Codexis to Hold 2016 First Quarter Conference Call on May 9
REDWOOD CITY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2016 financial results after market close on Monday, May 9, 2016.  Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results and provide a company update.  Live Call: U.S. 855 890 8665   Internationa... 
May 02, 2016
Codexis Completes CodeEvolver® Technology Transfer to GSK; Earns $7.5 Million Milestone Payment
REDWOOD CITY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the completion of the third and final Wave in the transfer of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK).  Codexis expects to receive a $7.5 million payment from GSK for completion of this milestone in the second quarter of 2016. “We are delighted to have successfully completed the first full transfer of our C... 
March 03, 2016
Codexis Reports 2015 Fourth Quarter and Full Year Financial Results
Meets 2015 Financial Guidance and Introduces 2016 Financial Guidance Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces financial results for the three and 12 months ended December 31, 2015, provides an update on the company's business progress and introduces 2016 financial guidance. “The fourth quarter marks the highest quarterly product revenues from o... 
March 03, 2016
Codexis Adds Life Sciences Industry Veteran David V. Smith to Its Board of Directors
REDWOOD CITY, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the appointment of David V. Smith to its Board of Directors, increasing the size of the Board to nine Directors. He brings to Codexis more than 30 years of financial and operational management experience that includes senior executive positions in multibillion-dollar life sciences companies. “David’s impressi... 
February 25, 2016
Codexis to Hold 2015 Fourth Quarter and Full Year Conference Call on March 3
REDWOOD CITY, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2015 financial results after market close on Thursday, March 3, 2016.  Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results and provide a company update.        Live Call: U.S. ... 
February 22, 2016
Codexis Files Lawsuit against EnzymeWorks and CEO Junhua “Alex” Tao for Patent Infringement and Misappropriation of Trade Secrets
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 22, 2016-- Codexis, Inc. (Nasdaq: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the filing of a lawsuit against EnzymeWorks and its founder, Junhua “Alex” Tao, for willful patent infringement, misappropriation of trade secrets, breach of confidence, and other claims. The suit was filed as Case No. 3:16-cv-00826-BLF in the United States District Court, ... 

Sign up for E-mail Alerts

You may automatically receive Codexis, Inc. information by e-mail




Enter your e-mail address here:
Print Page Print Page | E-mail Page E-mail Page |

Share Page

X
| Financial Tear Sheet Tear Sheet

WE ARE BIOCATALYSIS®

We are an industrial biotechnology company providing unique, state-of-the-art enzyme optmization services and biocatalyst products.


BIOCATALYSIS PRODUCTS

Codexis offers complete biocatalysis solutions from “off-the-shelf” enzymes and Screening Kits, to commercial supply of biocatalysts.

CODEXIS

CODEEVOLVER®


Our protein engineering technology enables the rapid development of custom-designed enzymes

CODEXIS

MEDIA CENTER


Visit our Media Center for the latest press information, videos, imagery, and technical papers.

CAREERS AT CODEXIS

Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do


CODEXIS

INVESTOR CENTER


Access to Codexis information for the investment community


built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue